In the period from 2000 to 2006, the Biolink Group has, as the only company in the world, synthesized and patented the two major anthocyanins Cyanidin 3-Glucopyranoside (BSC3G) and Deplhinidin 3-Glucopyranoside (BSD3G) for pharmaceutical industrial applications. These molecules are 100% identical to the natural ones. (The adjacent copies, hydroxyphenyl groups at the B-ring)(ortodihydroxy). Hence, they should be expected to be non-toxic.
As both of these two molecules retain the orthodihydroxyphenyl bindings on their B-ring, they have so far proven to be the two strongest biologically active molecules of the well-known anthocyanins. The industrial up-scaling of the synthetic Biolink Group molecules has been a significant challenge, but is steadily moving forwards.
Enlarging the process of synthetic molecules one million times from mg through KG to tons might at first appear an extremely challenging and difficult task. However, the number of steps in the synthesizing process has been reduced to an industrially feasible level, making up-scaling within a financially acceptable level, a realistic target.
At the moment, synthezicing of the most frequent metabolites from anthocyanins, are being done in an effort to extend the pharmaceutical potential of our knowledge within anthocyanins.
At the time being, clinical studies on the synthetic anthocyanin molecules BSCyanidin and BSDelphinidin
(In a prescribed mix), are taking place at university hospitals in Norway (Cardiovascular, Cancer, NF-kB…),
USA (Cancer) and the Peoples Republic of China (Metabolic Syndrome, NF-kB…).
In 2007, the Biolink Group synthetic anthocyanin molecules (BSCyanidin and DSDelphinidin) have only been supplied
in volumes to clinical studies in the purpose of drug development.
University hospitals and universities in Norway, China and USA are at the moment doing in vitro cell line studies
and in vivo animal studies on the synthetic anthocyanin molecules in different medical applications.
Application areas of synthetic anthocyanins
As soon as all non-toxic studies are finalized, we foresee a great international business opportunity in the
Human drug applications
Veterinarian drug applications
Fish farming drug applications
Functional food applications
The company’s goal within the drug related areas is going to be achieved by developing medical product platforms
based on its synthesized, patented anthocyanin molecules and their main metabolites.
In order to secure a success within a reasonable time frame, cooperation with an international pharmaceutical
company will be applied for at the latest when the pre clinic phase or phase 0 in drug development is finalized.
Financially healthy development in the medical area is to be ensured by strategic license agreements or partnership
with well established pharmaceutical companies.
The huge international vet market
As the synthetic molecules, BSCyanidin and BSDelphinidin (including their metabolites) in the up-scaling process
are getting dramatic less expensive, compared to the natural ones, applications within the Veterinarian market
are becoming an interesting reality. Potential applications for this market segment have already been the subject
of clinical studies only waiting for an industrial, economic feasible, solution.
Including possible modifications of BSC, BSD and metabolites, the vet market is expected carrying a multibillion